Evidence map›Paper›PMID 39583908›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2024

Normal-organ distribution of PSMA-targeting PET radiopharmaceutical

Ross Penny, Benjamin Fongenie, Phillip Davis, James Sykes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ross PennyBlue Earth Diagnostics Ltd. The Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA, UK.
Benjamin FongenieBlue Earth Therapeutics Ltd. The Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA, UK.
Phillip DavisBlue Earth Diagnostics Inc. No. 259 Prospect Plains Road, Building H, Suite 100, Monroe Township, New Jersey 08831, USA.
James SykesBlue Earth Diagnostics Ltd. The Oxford Science Park, Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-affinity radiohybrid PSMA-targeting radiopharmaceutical

methodsAll 718 evaluable

resultsIn total, scans from 546 patients (244 primary, 302 recurrent) were eligible for this analysis. All organs were considered to be normally distributed except for the bladder and spleen. In the liver, the mean SUV

conclusionsPhysiological

Indexed as

18F-flotufolastatBiodistributionliverpositron emission tomographyprostate-specific membrane antigenrhPSMA

Identifiers

PMID39583908
PMCPMC11578810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.